Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 02 May 2017, Paris - France

Session Details

Late Breaking Trials II: Focus on chronic heart failure
Sun 30 Apr 08:30 - 10:00 Miscellaneous Special Session, Mobile App - Ask a Question, Late Breaking Science HUGO -
Chairpersons: Frank RUSCHITZKA (Zurich, Switzerland), Eugene BRAUNWALD (Boston, United States of America)

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
08:30651The which heart failure intervention is most cost-effective in reducing hospital stay trial.Simon STEWART (Blackwood, Australia)
08:37652Discussion: The which heart failure intervention is most cost-effective in reducing hospital stay trial.William ABRAHAM (Columbus, US)
08:40653Global variations in mortality among patients with heart failure.Hisham DOKAINISH (Hamilton, Canada)
08:47654Discussion: Global variations in mortality among patients with heart failure.Carolyn Sp LAM (Singapore, SG)
08:50655Heart failure with mid ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire EF spectrum.Lars LUND (Stockholm, Sweden)
08:57656Discussion: CHARM.Massimo Francesco PIEPOLI (Piacenza, IT)
09:00657Empagliflozin decreases risk of kidney function decline in type 2 diabetes: slope analyses in patients with and without heart failure at baseline from the EMPA-REG OUTCOME trial.Alfred CHEUNG (Salt Lake City, United States of America)
09:07658Discussion: EMPA-REG OUTCOME.Giuseppe M C ROSANO (London, GB)
09:10659Targeting heart rate to improve mortality in heart failure with reduced ejection fraction: a comparison of sinus rhythm and atrial fibrillation.John CLELAND (Glasgow, United Kingdom)
09:17660Discussion: Targeting heart rate to improve mortality in heart failure with reduced ejection fraction: a comparison of sinus rhythm and atrial fibrillation.Michael BOEHM (Homburg/Saar, DE)
09:20661Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomised placebo-controlled trial.Michel KOMAJDA (Paris, France)
09:27662Discussion: EDIFY.Gerasimos FILIPPATOS (Athens, GR)